


Annual Meeting on Women's Cancer: 2024 in Review



3,351 registrants



Attendee Data

3.043 attended in-person



308 attended virtually



1,436 physician/scientists

474



exhibitors/vendors 459

trainees



157 advanced practice providers, registered nurses, and non-MD health professionals



73 personnel



60 patient advocates



47 SGO member



16



24% growth

in overall attendance over the course of five meetings

Education Data

610 presentations and posters:

62 oral presentations 36 featured posters 27 walking posters 466 poster presentations 19 surgical films



Number of sessions:

25 oral sessions 11 industry-supported symposia 4 rapid fire featured posters 6 walking posters

> 7 scientific and plenary 9 focused plenary 7 education forum

2 special interest 2 international



Impactful trials:

26 late-breaking



Continuing education:

26.75 enduring



40 impactful prospective trials presented:

11 quality improvement or feasibility trials, 3 Phase I trials

11 Phase II trials

15 Phase III trials

ttendance 3,351 2024 3,046 2023 2022 2,840 Year-Over-Year 2021 2,606 (Cancelled due to COVID-19) 2020 2,541 2019 1,837 2014 Number of attendees

The data presented here will change the way I view the gyn cancers landscape.

— 2024 Annual Meeting on Women's Cancer attendee

There are so many high-quality clinical trials presented in the meeting. I will participate or initiate the clinical trials in my future work.

- 2024 Annual Meeting on Women's Cancer attendee

For more information about the SGO Annual Meeting on Women's Cancer, please visit us at:

sgo.org/annualmeeting or scan the QR code at right.



Scan for more information!

For More Information